Metabolism and Target Organ Damage
@MetabolismAnd
Followers
826
Following
4K
Media
1K
Statuses
2K
A Gold Open Access peer-reviewed journal (ISSN: 2769-6375, Indexed in ESCI,#Scopus). #metabolism #metabolic #disorders #cardiovascular #liver #kidneys #pancreas
Xi'an, China
Joined April 2021
Join our Webinar Week (Oct 19–23)! 10 world-leading experts including Jacob George, Jean-François Dufour, Christopher Byrne & more will share cutting-edge insights on #MASLD, #HCC, obesity & metabolism. ✅ Free registration now: https://t.co/gweNfjU6ul
#livertwitter
0
1
1
🌟 New review published! “MetALD is emerging as a key contributor to liver disease. This review summarizes its mechanisms, diagnosis and therapeutic prospects. 📍 https://t.co/78By9E6ewN
#LiverDisease #Hepatology #Metabolism #AlcoholHealth
0
0
1
🧠🫀 Why do brain disorders and metabolic diseases overlap? A new comprehensive review uncovers the shared aging pathways driving both. Check out this insightful piece in Metabolism & Target Organ Damage! https://t.co/ZHazdiA0zI
#Geroscience #BrainHealth #Metabolism
0
0
2
🆕 Article Highlight Lower CBS & PEMT levels are associated with advanced NAFLD fibrosis Modeling suggests B-vitamins and betaine may help reduce Hcy levels 🔍 Explore the full study: https://t.co/QbHiQklZCm
#NAFLD #LiverDisease #Metabolism
0
1
1
🧠 New in M&TOD! This perspective explores how the NAFLD–MAFLD naming debate reflects deeper issues of power, participation, and equity in science. 🔗 https://t.co/puFRQfKxCu
#FattyLiver #Hepatology
0
0
1
🥳M&TOD rejoices as three Editorial Board members and two authors stand out at the Highly Cited Researchers List for 2025, released by @Clarivate. Share in the joy and excitement with us!🎉
0
0
1
🧬 Call for Papers! Wilson’s Disease: From Molecular Mechanisms to Clinical Management Guest Editors: Prof. Jiangao Fan & Prof. Jianshe Wang Deadline: Mar 8, 2026 If interested, feel free to contact the Editorial Office. 🔗 https://t.co/xiF6fP2uxU
#WilsonsDisease #CallForPapers
0
0
1
This review dives into how mechanobiology drives the development and progression of nonalcoholic fatty liver disease (NAFLD), highlighting the impact of cellular forces on liver fibrosis and disease dynamics. 🔗 https://t.co/a5ZUKw8no9
#NAFLD #LiverMechanobiology #CellBiology
1
0
0
📢 Now open for submissions! M&TOD Special Issue on ： Risk Factors for Type 2 Diabetes & Complications. Guest Editors: Hui Tian & Hongzhou Liu Deadline: July 1, 2026 🔗 https://t.co/p97njDAGPt
#DiabetesResearch #Type2Diabetes #MetabolicHealth #CallForPapers
0
0
0
This narrative review explores how obesity and bariatric surgery affect kidney function — diving into the renal benefits and risks of metabolic bariatric surgery. 🔗 https://t.co/27YH5gaEuE
#Obesity #BariatricSurgery #RenalResearch #MetabolicHealth
0
0
1
Researchers dive into why our current mouse models fall short for Primary Sclerosing Cholangitis (PSC) — and propose a new genetic model that could finally let us unravel this rare, complex liver disease. https://t.co/LtqVPZK7nR
#PSC #LiverResearch #AnimalModels
0
0
0
New findings! 🚨 Everyday chemical exposure in teens may raise MASLD risk — but physical activity could help buffer the impact. 🧬💪 #Health #Research #YouthHealth Read more: https://t.co/RfljWR77Ba
0
1
1
🧬 The review on Metabolic dysfunction‑associated steatotic liver disease (MASLD) highlights its extra-hepatic impact — from cardiovascular disease and chronic kidney disease to endocrine disorders and cancer. https://t.co/REd5WAD5tg
#MASLD #MultisystemDisease #LiverHealth
0
0
0
🧬 Call for Papers – M&TOD MAFLD Special Issue We welcome submissions on diagnostics, mechanisms, microbiota & clinical insights. Deadline: May 31, 2026. If interested, feel free to contact the Editorial Office. 🔗 https://t.co/2bBYfl0gKJ
#MAFLD #LiverResearch #CallForPapers
0
1
1
Weight loss is not the only success metric after metabolic bariatric surgery. This insightful article calls for standardized outcome measures that capture metabolic, functional, and quality-of-life benefits beyond the scale. 🔗 https://t.co/wCHq1fTUVo
#BariatricSurgery
0
0
4
Yohimbine alleviates diabetic kidney injury by activating the circGNB1–CDA1 axis, reducing oxidative stress and cell damage. A promising new mechanism for diabetic nephropathy therapy. 🔗 https://t.co/jIVcxN7uuy
#DiabeticNephropathy #RenalResearch #MolecularMechanism
0
0
1
🩺 MASLD is reshaping liver transplantation. A new M&TOD review explores how metabolic dysfunction impacts every stage — from donor selection to post-transplant outcomes. Read more 👉 https://t.co/diYe2Ek4eh
#LiverTransplant #MASLD #Hepatology
0
0
0
📑 A 20-year pharmacovigilance analysis in M&TOD reveals a significant upward trend in drug-induced fatty liver disease, particularly associated with monoclonal antibodies. https://t.co/IPDQZJEuVr
#Pharmacovigilance #Hepatology
0
0
0
🧬 New review: Noninvasive tests are now advancing fast to catch and stage Metabolic dysfunction‑associated steatotic liver disease (MASLD) early—reducing the need for liver biopsy. Dive in 👉 https://t.co/X8I0QmQvVf
#LiverHealth #Metabolism
0
0
0
Weight-loss surgery improves liver health 🫀—but may raise the risk of alcohol misuse later 🍷 New insights from Metabolism and Target Organ Damage: 🔗 https://t.co/UStsd7TKhX
#BariatricSurgery #LiverDisease #Metabolism
0
0
0
Watch Now! Don’t miss the inspiring talk by Prof. Amedeo Lonardo, Editor-in-Chief & Founding Editor of M&TOD, on “Sex Differences in MASLD.” 🔗 https://t.co/edfqHGXAZh
#MASLD #MetabolicDisease #Livertwitter @BlaneyMD @acv69cardenas @MikeVinikoor @AAFG_2021
0
0
2